Oppenheimer analyst Suraj Kalia initiates coverage on $Abbott Laboratories (ABT.US)$ with a buy rating, and sets the target price at $130.
According to TipRanks data, the analyst has a success rate of 53.1% and a total average return of 8.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Abbott Laboratories (ABT.US)$'s main analysts recently are as follows:
The industry's third-quarter utilization trends appeared favorable, even considering the customary summer seasonal reduction in elective procedures. There is also a positive sentiment among investors for MedTech stocks as the earnings season approaches, with expectations that interest will remain strong in high-performing and catalyst-driven stocks through the end of the year.
Abbott is characterized as a 'large-cap diversified healthcare play.' It presents a dual narrative with its compelling medical technology portfolio, which is responsible for 45% of its global sales of $42B and is growing at a rate of 11%-13% annually. On the other hand, its non-MedTech operations are expanding at a lower rate due to legal challenges impacting its pediatric nutrition segment and a decline in COVID-19 diagnostics sales. As these challenges in the non-MedTech sector diminish, Abbott is expected to experience an uptick in sales growth reaching low-double-digits by fiscal 2026, accompanied by an improvement in EBIT margins.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
奧本海默控股分析師Suraj Kalia首次給予$雅培 (ABT.US)$買入評級，目標價130美元。
根據TipRanks數據顯示，該分析師近一年總勝率為53.1%，總平均回報率為8.7%。
此外，綜合報道，$雅培 (ABT.US)$近期主要分析師觀點如下：
即使考慮到夏季按季節性減少選修程序，該行業第三季度的利用率趨勢似乎還是不錯的。隨着業績期的臨近，投資者對醫療科技股票也持樂觀情緒，預計到年底，對錶現優異和催化劑驅動的股票的興趣將保持強勁。
雅培被描述爲 「大盤股多元化醫療保健公司」。它以其引人注目的醫療技術產品組合呈現雙重敘事，佔其420億美元全球銷售額的45％，並且每年以11％-13％的速度增長。另一方面，由於法律挑戰影響其兒科營養領域以及 COVID-19 診斷產品銷售下降，其非醫療技術業務正以較低的速度擴張。隨着非醫療技術行業面臨的這些挑戰逐漸減弱，預計雅培的銷售增長將在2026財年之前達到低兩位數，同時息稅前利潤率也將提高。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
